IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice.


Journal

International journal of oral science
ISSN: 2049-3169
Titre abrégé: Int J Oral Sci
Pays: India
ID NLM: 101504351

Informations de publication

Date de publication:
02 01 2020
Historique:
received: 24 05 2019
accepted: 14 10 2019
entrez: 5 1 2020
pubmed: 5 1 2020
medline: 23 2 2020
Statut: epublish

Résumé

Odontogenic tumours are a heterogeneous group of lesions that develop in the oral cavity region and are characterized by the formation of tumoural structures that differentiate as teeth. Due to the diversity of their histopathological characteristics and clinical behaviour, the classification of these tumours is still under debate. Alterations in morphogenesis pathways such as the Hedgehog, MAPK and WNT/β-catenin pathways are implicated in the formation of odontogenic lesions, but the molecular bases of many of these lesions are still unknown. In this study, we used genetically modified mice to study the role of IKKβ (a fundamental regulator of NF-κB activity and many other proteins) in oral epithelial cells and odontogenic tissues. Transgenic mice overexpressing IKKβ in oral epithelial cells show a significant increase in immune cells in both the oral epithelia and oral submucosa. They also show changes in the expression of several proteins and miRNAs that are important for cancer development. Interestingly, we found that overactivity of IKKβ in oral epithelia and odontogenic tissues, in conjunction with the loss of tumour suppressor proteins (p53, or p16 and p19), leads to the appearance of odontogenic tumours that can be classified as ameloblastic odontomas, sometimes accompanied by foci of secondary ameloblastic carcinomas. These tumours show NF-κB activation and increased β-catenin activity. These findings may help to elucidate the molecular determinants of odontogenic tumourigenesis and the role of IKKβ in the homoeostasis and tumoural transformation of oral and odontogenic epithelia.

Identifiants

pubmed: 31900382
doi: 10.1038/s41368-019-0067-9
pii: 10.1038/s41368-019-0067-9
pmc: PMC6946653
doi:

Substances chimiques

RNA, Messenger 0
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1

Références

Oncotarget. 2017 Feb 21;8(8):14089-14106
pubmed: 27793042
Cell Death Dis. 2015 Jan 22;6:e1618
pubmed: 25611392
Nat Genet. 2001 Dec;29(4):418-25
pubmed: 11694875
J Hematol Oncol. 2013 Jan 15;6:6
pubmed: 23321005
Oncogene. 2014 Feb 6;33(6):702-12
pubmed: 23416980
J Dent Res. 2015 Jan;94(1):121-8
pubmed: 25376721
PLoS One. 2010 Dec 30;5(12):e15755
pubmed: 21209895
Genes Chromosomes Cancer. 2009 Jul;48(7):569-82
pubmed: 19396866
Genes (Basel). 2017 Dec 08;8(12):
pubmed: 29292732
Nat Commun. 2015 Apr 07;6:6658
pubmed: 25849741
J Oral Pathol Med. 2012 May;41(5):389-93
pubmed: 22082131
EMBO J. 2018 Dec 14;37(24):
pubmed: 30467221
J Oral Maxillofac Pathol. 2016 May-Aug;20(2):289-99
pubmed: 27601825
J Invest Dermatol. 2010 Jun;130(6):1598-610
pubmed: 20200541
Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
Cell Death Differ. 2010 Feb;17(2):193-9
pubmed: 19461653
Mol Cancer Res. 2017 Sep;15(9):1255-1264
pubmed: 28584022
Oncotarget. 2016 Apr 12;7(15):20902-18
pubmed: 26959115
Arch Oral Biol. 2009 Oct;54(10):893-7
pubmed: 19679296
Oncol Lett. 2012 May;3(5):955-960
pubmed: 22783372
Genes Dev. 2004 Nov 15;18(22):2736-46
pubmed: 15520276
Front Genet. 2017 Mar 28;8:31
pubmed: 28400788
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Mol Cancer Res. 2011 Oct;9(10):1329-38
pubmed: 21821676
J Oral Maxillofac Pathol. 2016 Sep-Dec;20(3):497-504
pubmed: 27721617
Dev Dyn. 2012 Sep;241(9):1465-72
pubmed: 22753148
Cell. 1997 Nov 28;91(5):649-59
pubmed: 9393858
EMBO Rep. 2014 Jan;15(1):46-61
pubmed: 24375677
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18627-32
pubmed: 17121988
Arch Oral Biol. 2018 Mar;87:211-217
pubmed: 29310033
Head Neck Pathol. 2017 Mar;11(1):68-77
pubmed: 28247226
Dev Biol. 2008 Jan 1;313(1):210-24
pubmed: 18022614
Cancer Res. 2009 Feb 1;69(3):1099-108
pubmed: 19176372
Sci Rep. 2015 Sep 28;5:14479
pubmed: 26411543
J Cell Sci. 2013 Jul 1;126(Pt 13):2877-89
pubmed: 23613467
Tumour Biol. 2017 Mar;39(3):1010428317695920
pubmed: 28347239
Med Oral Patol Oral Cir Bucal. 2017 May 1;22(3):e324-e332
pubmed: 28390135
Nat Genet. 2010 Jul;42(7):599-603
pubmed: 20512145

Auteurs

Angustias Page (A)

Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Instituto de Investigación 12 de Octubre i+ 12, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Ana Bravo (A)

Department of Anatomy, Animal Production and Veterinary Clinical Sciences, Laboratory of Pathology Phenotyping of Genetically Engineered Mice, Faculty of Veterinary Medicine, University of Santiago de Compostela, Lugo, Spain.

Cristian Suarez-Cabrera (C)

Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Instituto de Investigación 12 de Octubre i+ 12, Madrid, Spain.

Raquel Sanchez-Baltasar (R)

Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Instituto de Investigación 12 de Octubre i+ 12, Madrid, Spain.

Marta Oteo (M)

Biomedical Applications and Pharmacokinetics Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.

Miguel Angel Morcillo (MA)

Biomedical Applications and Pharmacokinetics Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.

M Llanos Casanova (ML)

Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Instituto de Investigación 12 de Octubre i+ 12, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Jose C Segovia (JC)

Hematopoietic Innovative Therapies Division. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Unidad Mixta de Terapias Avanzadas. Fundación Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz, Madrid, Spain.

Manuel Navarro (M)

Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Instituto de Investigación 12 de Octubre i+ 12, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Angel Ramirez (A)

Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. a.ramirez@ciemat.es.
Instituto de Investigación 12 de Octubre i+ 12, Madrid, Spain. a.ramirez@ciemat.es.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. a.ramirez@ciemat.es.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH